Table 3.
Vaccination strategies following autologous stem cell transplantation
| Vaccine | SoR/QoE | Time post-SCT (months) | Doses | Comment |
|---|---|---|---|---|
| Influenza | AIIt | 3–6 | 1–2 | Improved seroprotection with two doses (BIIt) |
| Pneumococci | AIIt | 3–6 | 4 | Three doses PCV13 followed by one dose PPSV23 |
| Tetanus | BIIu | 6–12 | 3 | |
| Diphtheria | BIIu | 6–12 | 3 | Full dose (“D”) preferred (BIII) |
| Pertussis | CIII | 6–12 | 3 | Full dose acellular vaccine (aP) preferred |
| Poliomyelitis | BIIt | 6–12 | 3 | Inactivated vaccine only |
| HiB | BIIt | 6–12 | 3–4 | Conjugate vaccine preferred |
| Meningococci | BIIt | 6–12 | 1–2 | Conjugate vaccine preferred |
| Hepatitis B | BIIt | 6–12 | 3 | |
| Measles | BIIt | 24 | 1–2 | No live vaccine < 24 months post ASCT (DIIt) |
| Mumps | BIIt | 24 | 1–2 | No live vaccine < 24 months post ASCT (DIIt) |
| Rubella | BIIt | 24 | 1–2 | No live vaccine < 24 months post ASCT (DIIt) |
| Varicella | AIIt | 24 | 1–3 | No live vaccine < 24 months post ASCT (DIIt) |
Strength of recommendation (SoR) and quality of evidence (QoE) according to the ESCMID grading system is given for each vaccine preventable disease as well as the recommended time point and number of doses of vaccination. Further details are given in the text.